Trade BioCryst - BCRX CFD

BioCryst Company profile

BioCryst (BCRX) is a commercial-stage biotech firm that discovers novel, oral, small-molecule medicines. 

The company focuses on oral treatments for rare diseases in which significant unmet medical needs exist. BioCryst’s drug portfolio consists of ORLADEYO for prevention of hereditary angioedema. ORLADEYO has been approved in the US, EU, UK, Japan and UAE. Other drugs like RAPIACTA, RAPIVAB and PERAMIFLU are approved in select geographies. 

The company is developing an oral small molecule Factor D inhibitor to treat patients with paroxysmal nocturnal hemoglobinuria and other complement-mediated diseases.

According to the company, its focus on rare diseases market helps it control costs effectively. BioCryst selects disease targets and product candidates in which a small molecule would offer a significant benefit over existing products or would be the first to market.

BioCryst’s US headquarters is located in Durham, North Carolina while its European headquarters is in Dublin, Ireland. Jon P Stonehouse is the chief executive officer and William P Sheridan is the chief medical officer of BioCryst.

The company was founded in 1966. It completed its initial public offering (IPO) in March 1994 and is listed on the Nasdaq stock exchange under the ticker symbol BCRX. According to the company’s price history, BCRX stock price hit an all-time high of $37.25 on 1 March 2000. 

You can follow the ups and downs of the BioCryst stock price at Capital.com. Always stay on top of the latest price developments with our live BCRX stock chart.